Navigation Links
VisEn Launches New Cat B 750 Fast(TM) Fluorescence Molecular Imaging Agent at American Heart Association Meeting
Date:11/12/2009

ORLANDO, Fla., Nov. 12 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 750 FAST(TM) imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo. Cathepsin B expression is well known as a key biomarker and therapeutic target in a range of diseases, including atherosclerosis, oncology, and arthritis. The new agent is expected to have a significant impact in cardiovascular disease research, and is being launched at the American Heart Association Scientific Sessions 2009 in Orlando.

Cathepsin B proteases play an important role in disease progression and host response in several disease areas, and are key biomarkers in assessing and characterizing disease states. The new Cat B 750 FAST(TM) agent is designed to complement in vitro and in vivo protease readouts from cell-based assays and VisEn's existing in vivo agent product lines, providing earlier imaging time points and narrower specificity profiles of cathepsin B within the cathepsin family of proteases.

The new Cat B 750 FAST(TM) agent represents an additional protease-sensing agent developed from VisEn's new FAST ("Fluorescent Activatable Sensor Technology") in vivo agent platform. FAST agents are based on high-performance activatable smaller molecules that combine advanced biomarker specificity with optimized biocompatibility and rapid pharmacokinetics. These benefits allow for precise measurement and monitoring of key disease biomarkers in vivo.

VisEn also announced the commercial availability of its ReninSense680 FAST(TM) agent for localized in vivo measurement of changes in renin-angiotensin system (RAS) involved in hypertension and some neurological diseases.

"We continue to be very pleased with the rapidly expanding capability and adoption of our fluorescence agents and FMT imaging systems as a standard in measuring key biologic pathways and biomarkers in vivo," said Kirtland Poss, President and CEO of VisEn. "We look forward to working further with our customers in advancing their research and therapeutic development in these important disease areas."

VisEn's proprietary fluorescence imaging agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts in vivo. VisEn offers over 30 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways. VisEn agent brands include ProSense®, IntegriSense(TM), AngioSense(TM), OsteoSense®, MMPSense(TM), Cat K FAST(TM), Annexin-Vivo(TM), and now ReninSense FAST and Cat B FAST. VisEn also offers specialized lines of in vivo agent labeling platforms, including its proprietary VivoTag® fluorescence labeling dyes for custom agent development and its NanoSpark® labeling nanoparticles. They are all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in in vivo imaging.

All VisEn agents and labels are designed for in vivo biomarker quantification using VisEn's Fluorescence Molecular Tomography (FMT(TM)) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems. VisEn agents are also designed to enable complementary in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and cellular-based imaging systems. With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT(TM)) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical and clinical partners to design ranges of tailored molecular imaging agents and applications designed for their specific pre-clinical and clinical research areas.

Additional information can be found at www.visenmedical.com.

SOURCE VisEn Medical Inc.


'/>"/>
SOURCE VisEn Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
2. VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE
3. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
4. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
5. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
6. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
9. Premier Micronutrient Launches Supplement for Hearing Health
10. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
11. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 9, 2016   AllCare Plus Pharmacy announced ... Seal of Approval ® for Home Care ... standards. The Gold Seal of Approval ® is ... to providing safe and effective care.  ... underwent a rigorous on-site survey in January 2016. The ...
(Date:2/9/2016)... Feb. 9, 2016 The new report "Global Diagnostic Ultrasound ... & Consulting group reveals that global diagnostic ultrasound devices market was ... to US$ 7,466.3 million by 2019 at a CAGR of 6.8% ... global ultrasound market has been analyzed for six geographies of ... Asia-Pacific , Latin America , ...
(Date:2/9/2016)... , Feb. 9, 2016 The global ... 2014, and it is expected to grow with a ... the glass prefilled syringes segment dominated the global prefilled ... --> --> The global market ... rate, due to increasing geriatric population, increasing demand for ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... IsoComforter, ... the introduction of the newly designed, innovative shoulder wrap. The newly designed ... coverage for the injured arm and shoulder to promote faster healing. It is ...
(Date:2/9/2016)... ... February 09, 2016 , ... Sir ... company , is proud to announce that many of their franchises have received ... service. The hard surface restoration franchises received customer recognition through positive reviews and ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... officially been won. A team from 21st Century Medicine (21CM) ( http://www.21cm.com/ ... preserve the delicate neural circuits of an intact rabbit brain for extremely long-term ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... authorization with BASF Human Nutrition into the Food & Beverage and ... has been BASF’s channel partner throughout Canada and USA geographies east of the ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Valentine’s Season is famous for gift giving with flowers, chocolates ... they are loved. This year, for more than 5.6 million Americans suffering with Alzheimer’s, ... be enough to remind them of the lives they’ve led and the people they’ve touched. ...
Breaking Medicine News(10 mins):